Compare SEQUENT SCIENTIFIC with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SEQUENT SCIENTIFIC vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SEQUENT SCIENTIFIC AUROBINDO PHARMA SEQUENT SCIENTIFIC/
AUROBINDO PHARMA
 
P/E (TTM) x 52.2 6.9 758.8% View Chart
P/BV x 5.8 1.6 350.4% View Chart
Dividend Yield % 0.3 0.6 46.1%  

Financials

 SEQUENT SCIENTIFIC   AUROBINDO PHARMA
EQUITY SHARE DATA
    SEQUENT SCIENTIFIC
Mar-21
AUROBINDO PHARMA
Mar-21
SEQUENT SCIENTIFIC/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2651,023 25.9%   
Low Rs70333 21.0%   
Sales per share (Unadj.) Rs54.8422.8 13.0%  
Earnings per share (Unadj.) Rs4.292.0 4.6%  
Cash flow per share (Unadj.) Rs6.2110.0 5.7%  
Dividends per share (Unadj.) Rs0.504.00 12.5%  
Avg Dividend yield %0.30.6 50.6%  
Book value per share (Unadj.) Rs29.0374.3 7.7%  
Shares outstanding (eoy) m248.37585.94 42.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x3.11.6 190.4%   
Avg P/E ratio x39.87.4 540.0%  
P/CF ratio (eoy) x26.86.2 435.0%  
Price / Book Value ratio x5.81.8 318.8%  
Dividend payout %11.94.3 273.4%   
Avg Mkt Cap Rs m41,590397,398 10.5%   
No. of employees `000NANA-   
Total wages/salary Rs m1,87235,350 5.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m13,616247,746 5.5%  
Other income Rs m843,809 2.2%   
Total revenues Rs m13,700251,555 5.4%   
Gross profit Rs m2,03281,480 2.5%  
Depreciation Rs m50610,554 4.8%   
Interest Rs m244745 32.7%   
Profit before tax Rs m1,36673,990 1.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32220,098 1.6%   
Profit after tax Rs m1,04553,892 1.9%  
Gross profit margin %14.932.9 45.4%  
Effective tax rate %23.627.2 86.7%   
Net profit margin %7.721.8 35.3%  
BALANCE SHEET DATA
Current assets Rs m7,667198,235 3.9%   
Current liabilities Rs m5,140106,652 4.8%   
Net working cap to sales %18.637.0 50.2%  
Current ratio x1.51.9 80.2%  
Inventory Days Days3119 161.4%  
Debtors Days Days9352 179.8%  
Net fixed assets Rs m6,763135,778 5.0%   
Share capital Rs m497586 84.8%   
"Free" reserves Rs m6,702218,713 3.1%   
Net worth Rs m7,199219,299 3.3%   
Long term debt Rs m9371,684 55.6%   
Total assets Rs m14,430334,013 4.3%  
Interest coverage x6.6100.3 6.6%   
Debt to equity ratio x0.10 1,695.1%  
Sales to assets ratio x0.90.7 127.2%   
Return on assets %8.916.4 54.6%  
Return on equity %14.524.6 59.0%  
Return on capital %19.833.8 58.5%  
Exports to sales %053.8 0.0%   
Imports to sales %016.4 0.0%   
Exports (fob) Rs mNA133,248 0.0%   
Imports (cif) Rs mNA40,615 0.0%   
Fx inflow Rs m686133,248 0.5%   
Fx outflow Rs m28144,946 0.6%   
Net fx Rs m40588,302 0.5%   
CASH FLOW
From Operations Rs m1,14833,289 3.4%  
From Investments Rs m965,987 1.6%  
From Financial Activity Rs m-1,388-13,648 10.2%  
Net Cashflow Rs m-14425,831 -0.6%  

Share Holding

Indian Promoters % 0.0 48.8 -  
Foreign collaborators % 53.0 3.1 1,727.0%  
Indian inst/Mut Fund % 8.6 37.9 22.6%  
FIIs % 6.4 21.4 30.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 47.0 48.2 97.5%  
Shareholders   167,812 341,568 49.1%  
Pledged promoter(s) holding % 0.0 24.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SEQUENT SCIENTIFIC With:   SUN PHARMA    LUPIN    CIPLA    DR. REDDYS LAB    CADILA HEALTHCARE    



Today's Market

Sensex, Nifty Recover from Day's Low to End Higher; Maruti Suzuki Hits New High Post Q3 Results(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

SEQUENT SCIENTIFIC 2020-21 Annual Report Analysis (Annual Result Update)

Oct 25, 2021 | Updated on Oct 25, 2021

Here's an analysis of the annual report of SEQUENT SCIENTIFIC for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SEQUENT SCIENTIFIC. Also includes updates on the valuation of SEQUENT SCIENTIFIC.

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

Aurobindo Pharma's Stock Falls After Profits Decline 7% (Views On News)

Jun 1, 2021

Aurobindo Pharma shares fell nearly 4% after quarterly earnings disappoint.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SEQUENT SCIENTIFIC SHARE PRICE


Jan 25, 2022 (Close)

TRACK SEQUENT SCIENTIFIC

  • Track your investment in SEQUENT SCIENTIFIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SEQUENT SCIENTIFIC

SEQUENT SCIENTIFIC 5-YR ANALYSIS

COMPARE SEQUENT SCIENTIFIC WITH

MARKET STATS